Literature DB >> 29850532

A Missense Mutation in POU4F3 Causes Midfrequency Hearing Loss in a Chinese ADNSHL Family.

Xue Gao1,2, Jin-Cao Xu2, Wei-Qian Wang2, Yong-Yi Yuan1, Dan Bai3, Sha-Sha Huang1, Guo-Jian Wang1, Yu Su1, Jia Li2, Dong-Yang Kang1, Mei-Guang Zhang2, Xi Lin4, Pu Dai1.   

Abstract

Hereditary nonsyndromic hearing loss is extremely heterogeneous. Mutations in the POU class 4 transcription factor 3 (POU4F3) are known to cause autosomal dominant nonsyndromic hearing loss linked to the loci of DFNA15. In this study, we describe a pathogenic missense mutation in POU4F3 in a four-generation Chinese family (6126) with midfrequency, progressive, and postlingual autosomal dominant nonsyndromic hearing loss (ADNSHL). By combining targeted capture of 129 known deafness genes, next-generation sequencing, and bioinformatic analysis, we identified POU4F3 c.602T>C (p.Leu201Pro) as the disease-causing variant. This variant cosegregated with hearing loss in other family members but was not detected in 580 normal controls or the ExAC database and could be classified as a "pathogenic variant" according to the American College of Medical Genetics and Genomics guidelines. We conclude that POU4F3 c.602T>C (p.Leu201Pro) is related to midfrequency hearing loss in this family. Routine examination of POU4F3 is necessary for the genetic diagnosis of midfrequency hearing loss.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29850532      PMCID: PMC5904794          DOI: 10.1155/2018/5370802

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Hearing loss is a common sensory defect in humans. Nonsyndromic hereditary forms, in which hearing loss is the only clinical sign, are known to be genetically heterogeneous. So far, more than 30 genes responsible for autosomal dominant nonsyndromic hearing loss (ADNSHL) have been identified (Hereditary Hearing Loss homepage, http://hereditaryhearingloss.org). Most patients with ADNSHL show large variations in age of onset and degrees of variety. According to the affected frequency, the phenotypes are divided into low-frequency, midfrequency, high-frequency, and all-frequency hearing loss. Midfrequency hearing loss (i.e., a U-shape audiogram) is a rare form of hearing loss, and six associated genes have been reported to date: EYA4, TECTA, COL11A2, CCDC50, POU4F3, and SLC44A4 [1-6]. Thus, in clinical molecular diagnosis, the hearing loss phenotype in a patient can aid the selection of a limited number of genes for mutational analysis. This study identified one Chinese family with ADNSHL (number 6126), in which affected individuals showed typical midfrequency hearing loss. Using next-generation sequencing, we performed large-scale mutational screening of 129 known deafness-related genes and identified one novel dominant disease-segregating mutation, c.602T>C (p.Leu201Pro) in the POU4F3 gene, as the causative mutation that led to the midfrequency hearing loss phenotype in this family.

2. Materials and Methods

2.1. Clinical Data

Family 6126 is a four-generation Chinese family with autosomal dominant, late onset, progressive, nonsyndromic sensorineural hearing loss. Fully informed written consent was attained from each subject or their guardians. The study was approved by the Chinese PLA General Hospital's ethics research committees. Clinical information was gathered through multiple interviews with all participating members of the family. Medical history collection, otoscopy, physical examination, pure tone audiometric examination, and vestibular function were performed as previously described [7]. CT scans of the temporal bone in the index patients were performed.

2.2. DNA Preparation

Genomic DNA was extracted from peripheral blood using a blood DNA extraction kit according to the manufacturer's instructions (TianGen, Beijing, China).

2.3. Deafness Gene Capture and Illumina Library Preparation

Three prevalent deafness-associated genes, GJB2, SLC26A4, and mtDNA12SrRNA, were first screened for mutations in all participating cases and controls. Two affected individuals (II:1 and III:1) and one unaffected individual (II:3) of family 6126 were subjected to a gene panel containing 129 deafness genes. Capture and NGS of the coding exons for the 129 deafness genes and their flanking 100 bps (Supplemental Table 1) were performed on an Illumina HiSeq 2000 by Otogenetics Corporation (Norcross, GA, USA). The details of the deafness gene capture, sequencing, and bioinformatics analysis methods have been described in detail previously [8]. According to the autosomal dominant pattern of inheritance, only variants that were heterozygous in the affected siblings were selected as candidates. Segregation of the POU4F3 c.602T>C (p.Leu201Pro) variant was tested in seven family members (II:1, II:3, II:4, II:5, III:1, III:2, and IV:1), including the three whose gDNA had been subjected to NGS screening, using polymerase chain reaction (PCR) (primer sequences available on request) followed by bidirectional Sanger sequencing. Sequence alterations were identified by alignment with the POU4F3 GenBank sequence (NM_002700.2 and NP_002691.1) using the GeneTools software. To identify pathogenic mutations, cosegregation analysis was performed with the family members and an in-house database of 481 Chinese controls with normal hearing.

2.4. Multiple Sequence Alignment

Multiple sequence alignment was performed according to a Homologene program with default settings and the sequences NP_002691.1 (H. sapiens), XP_001100319.1 (M. mulatta), XP_527063.1 (P. troglodytes), XP_544328.1 (C. lupus), NP_001178964.1 (B. taurus), NP_620395.2 (M. musculus), NP_001102359.1 (R. norvegicus), NP_990090.1 (G. gallus), NP_571353.1 (D. rerio), NP_524876.1 (D. melanogaster), XP_308015.5 (A. gambiae), and XP_002935313.1 (X. tropicalis) (https://www.ncbi.nlm.nih.gov/homologene?cmd=Retrieve&dopt=MultipleAlignment&list_uids=2023).

3. Results

3.1. Family and Clinical Evaluations

Family 6126 is a four-generation Chinese family with ADNSHL (Figure 1) and includes six affected patients: II:1 (female, 69 years old), II:4 (female, 60 years old), II:5 (female, 57 years old), III:1 (female, 42 years old), and IV:1 (female, 11 years old). For this family, hearing impairment was postlingual, late onset (after 10 years old), and progressive. Their hearing loss progressed gradually with advancing age. Audiograms show that although low-frequency and high-frequency hearing were normal in the beginning, their hearing would ultimately deteriorate at all frequencies. Flatter audiogram configurations were observed at 69 years of age (II:1), whereas the audiograms of III:1 and IV:1 were U-shaped (Figure 1(c)). For affected subjects II:4 and II:5, audiograms were unavailable.
Figure 1

Pedigree, mutational analysis, and audiogram of Chinese family 6126 with ADNSHI. (a) The proband is indicated by an arrow. Subjects II:1, II:3 and III:1 were tested by NGS. (b) DNA sequencing profile showing the POU4F3 c.602T>C cosegregated with the hearing loss. (c) Audiogram showed bilateral sensorineural hearing impairment of affected subjects II:1, III:1, and IV:1 (red: right ear; blue: left ear).

Detailed vestibular analysis was performed in III:1, who did not complain about dizziness, vertigo, or imbalance. Vestibular tests revealed normal vestibular function via caloric tests. All position tests produced no nystagmus without vertigo sensation. Affected individuals did not have obvious delayed gross motor development. The physical examinations of all participating members revealed no signs of systemic illness or dysmorphic features. High-resolution computed tomography of the temporal bone in III:1 was normal, excluding inner ear malformations. This phenotype was consistent with that reported for DFNA15.

3.2. Mutation Detection and Analysis

We sequenced all the coding exons plus ~100 bp of the flanking intronic sequence of 129 deafness genes in one unaffected (II:4) individual and two affected (II:1 and III:1) individuals of family 6126. One variant leading to amino acid change was detected in POU4F3: c.602T>C (p.Leu201Pro), which is located within exon 2 (Figure 2(a)). This variant has not been reported previously nor found in the ExAC database (http://exac.broadinstitute.org/) and was not observed in the 481 Chinese controls with normal hearing. The substitution occurred in an evolutionarily conserved region across different species in the POU domain (Figure 2(b)) and is predicted to be damaging by SIFT, Polyphen2, and CADD.
Figure 2

Conservation analysis and genomic structure of POU4F3 based on the open reading frame (NM_002700.2) containing 2 exons (black rectangles). (a) The position of POU4F3 c.602T>C (p.Leu201Pro) is highlighted in red and shown both at the gene (top) and the protein level (bottom). The protein diagram depicts the predicted functional domains and sequence motifs. (b) Protein alignment showing POU4F3 p.Leu201 occurred at evolutionarily conserved amino acids (in red box) across twelve species.

Using Sanger sequencing, seven participating family members (five affected and two unaffected) in family 6126 were genotyped to identify the mutation. POU4F3 heterozygous variant p.Leu201Pro was found in five patients (Figure 1), consistent with autosomal dominant inheritance. These data, together with the clinical presentation of the affected siblings and consistent autosomal dominant inheritance of the mutations in the affected and unaffected members, indicate that POU4F3 c.602T>C (p.Leu201Pro) is the cause of hearing impairment in this family.

4. Discussion

Inner ear hair cells play a crucial role in the mechanical transmission of sound and stimulation of the auditory nerve. A defect in hair cells in the cochlea can be a major reason for sensorineural hearing loss. POU4F3, a POU domain class IV protein, has two exons and encodes a protein of 338 amino acids that belongs to the POU domain family of transcription factors, which are expressed specifically in inner ear hair cells and play a critical role in the maturation, differentiation, and maintenance of inner ear hair cells [9]. POU4F3 contains two conserved DNA-binding domains (a POU-specific domain and a POU homeodomain; amino acids 179–256 and 274–333, resp.), which are the main functional parts [10]. In 1998, POU4F3 was first described as a disease-causing gene within the DFNA15 locus in an Israeli Jewish family [11]. So far, 27 variants in POU4F3 (13 missense variants, 8 frameshift variants, 4 nonsense variants, and 1 splice-site variant) (Table 1) and a whole deletion of POU4F3 [12] have been reported to cause ADNSHL with variable ages of onset and degrees of severity in various ethnic groups, including Chinese, Japanese, Dutch, Korean, and Brazilian populations [6, 10, 13–18]. Recently, Kitano et al. reported that POU4F3 variants represent the third largest cause of ADNSHL (2.5%, 15/602) in Japan and usually presented with mid- or high-frequency hearing loss. They also noticed that patients with truncating variants showed earlier onset and slower progression of hearing loss compared to those with nontruncating variants [6]. Through next-generation sequencing, He et al. reported that mutation in POU4F3 is a relatively common (3/18) cause of ADNSHL among Han Chinese people. Notably, most causative variants were located within or close to the POU-specific domain or the POU homeodomain, the two conserved DNA-binding domains of POU4F3 encoded in exon 2. The age of onset of hearing loss, ranging from the first to fourth decade of life, differs among POU4F3 mutations. In the present study, the earliest age of onset of hearing loss for affected family members was recorded at 11 years old (IV:1). Although the pathogenic mechanisms underlying hearing impairment of patients with POU4F3 variants remain unclear, the mechanism of haploinsufficiency has been supported by several studies [12, 19, 20].
Table 1

Overview of POU4F3 mutations described in DFNA15.

NumberNucleotide changeProtein changeExonDomainOriginAudiometric configurationReference
(1)Whole deletion of POU4F3 BrazilFlat and HF Freitas et al., 2014
(2)c.74dupAp.His25fs181JapanHF Kitano et al., 2017
(3)c.120+1G>C1ChinaFlat He et al., 2016
(4)c.191A>Tp.Asp64Val2JapanHF Kitano et al., 2017
(5)c.337C>Tp.Gln113Ter2China Zhang et al., 2016
(6)c.367delAp.Ile123fs32JapanMF Kitano et al., 2017
(7)c.427C>Tp.Gln143Ter2JapanMF Kitano et al., 2017
(8)c.491C>Gp.Pro164Arg2POUChinaFlat and HF Wei et al., 2014
(9)c.574G>Tp.Glu192Ter2POUJapanHF Kitano et al., 2017
(10)c.581T>Ap.Phe194Tyr2POUJapanHF Kitano et al., 2017
(11)c.602T>Cp.Leu201Pro2POUChinaMFThis study
(12)c.602delTp.Leu201fs32POUChinaHF Cai et al., 2016
(13)c.603_604delGG 2p.Val203Aspfs112POUChinaN/A Yang et al., 2013
(14)c.662_675del14p.Gly221Glufs142POUKoreaHF Lee et al., 2010
(15)c.665C>Tp.Ser222Leu2POUJapanHF Kitano et al., 2017
(16)c.668T>Cp.Leu223Pro2POUThe NetherlandsFlat, MF, and HF Collin et al., 2008
(17)c.680delCp.Thr227fs132POUJapanMF Kitano et al., 2017
(18)c.694G>Ap.Glu232Lys2POUKoreaHF Baek et al., 2012
(19)c.718A>Tp.Asn240Tyr2POUJapanMF Kitano et al., 2017
(20)c.841A>Gp.Ile281Val2POU HomeoboxJapanHF Kitano et al., 2017
(21)c.865C>Tp.Leu289Phe2POU HomeoboxThe NetherlandsFlat, MF, and HF Collin et al., 2008
(22)c.884_891del8Ile295Thrfs52POU HomeoboxIsraelHF Vahava et al., 1998
(23)c.896C>Tp.Pro299Leu2POU HomeoboxJapanMF Kitano et al., 2017
(24)c.932T>Cp.Leu311Pro2POU HomeoboxChinaHF He et al., 2016
(25)c.976A>Tp.Arg326Ter2POU HomeoboxJapanHF Kitano et al., 2017
(26)c.977G>Ap.Arg326Lys2POU HomeoboxKoreaHF Kim et al., 2013
(27)c.982A>Gp.Lys328Glu2POU HomeoboxTaiwanHF Lin et al., 2017
(28)c.1007delCp.Ala336fs2POU HomeoboxJapanN/A Mutai et al., 2013

Abbreviations. HF: high-frequency hearing loss; MF: midfrequency hearing loss.

The missense mutation p.Leu201Pro is located within the POU domain and encodes a proline at position 201 instead of the highly conserved leucine, which is close to the two reported dominant mutations of POU4F3 (c.603-604delGG [p.Leu201fs∗12] and c.602delT [p.Leu201fs]) [21, 22]. We speculate that to some extent, this area of the genome is unstable and susceptible to mutation. In this study, we identified a novel missense mutation, c.602T>C in POU4F3, in one Chinese family (6216) with ADNSHL. Younger patients in this family demonstrated midfrequency hearing loss with no additional clinical symptoms. Our results strongly suggest that this missense mutation is related to hearing loss in this family, which has a putative autosomal dominant inheritance pattern.

5. Conclusions

In summary, we describe the clinical and genetic characteristics of a Chinese family (number 6126) with postlingual ADNSHL caused by POU4F3 c. 602 T>C (p. Leu201Pro) through multiple deafness gene capture and next-generation sequencing. Notably, the hearing impairment of affected individuals in this family is mainly midfrequency. This specific audiogram should be considered in clinical genetic diagnosis and counselling. Therefore, screening for POU4F3 in ADNSHL patients with a postlingual, progressive, and U-shape audiogram is necessary for efficient genetic diagnosis and intervention.
  22 in total

1.  Role of transcription factors Brn-3.1 and Brn-3.2 in auditory and visual system development.

Authors:  L Erkman; R J McEvilly; L Luo; A K Ryan; F Hooshmand; S M O'Connell; E M Keithley; D H Rapaport; A F Ryan; M G Rosenfeld
Journal:  Nature       Date:  1996-06-13       Impact factor: 49.962

2.  Mutations in the transcriptional activator EYA4 cause late-onset deafness at the DFNA10 locus.

Authors:  S Wayne; N G Robertson; F DeClau; N Chen; K Verhoeven; S Prasad; L Tranebjärg; C C Morton; A F Ryan; G Van Camp; R J Smith
Journal:  Hum Mol Genet       Date:  2001-02-01       Impact factor: 6.150

3.  Mutations in COL11A2 cause non-syndromic hearing loss (DFNA13).

Authors:  W T McGuirt; S D Prasad; A J Griffith; H P Kunst; G E Green; K B Shpargel; C Runge; C Huybrechts; R F Mueller; E Lynch; M C King; H G Brunner; C W Cremers; M Takanosu; S W Li; M Arita; R Mayne; D J Prockop; G Van Camp; R J Smith
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

4.  Mutation in transcription factor POU4F3 associated with inherited progressive hearing loss in humans.

Authors:  O Vahava; R Morell; E D Lynch; S Weiss; M E Kagan; N Ahituv; J E Morrow; M K Lee; A B Skvorak; C C Morton; A Blumenfeld; M Frydman; T B Friedman; M C King; K B Avraham
Journal:  Science       Date:  1998-03-20       Impact factor: 47.728

5.  Deletion of the entire POU4F3 gene in a familial case of autosomal dominant non-syndromic hearing loss.

Authors:  Érika L Freitas; Jeanne Oiticica; Amanda G Silva; Roseli S M Bittar; Carla Rosenberg; Regina C Mingroni-Netto
Journal:  Eur J Med Genet       Date:  2014-02-18       Impact factor: 2.708

6.  A genotype-phenotype correlation with gender-effect for hearing impairment caused by TECTA mutations.

Authors:  Markus Pfister; Holger Thiele; Guy Van Camp; Erik Fransen; Fazil Apaydin; Omer Aydin; Peter Leistenschneider; Marcella Devoto; Hans-Peter Zenner; Nikolaus Blin; Peter Nürnberg; Haluk Ozkarakas; Susan Kupka
Journal:  Cell Physiol Biochem       Date:  2004

7.  Mutation in the Hair Cell Specific Gene POU4F3 Is a Common Cause for Autosomal Dominant Nonsyndromic Hearing Loss in Chinese Hans.

Authors:  Longxia He; Xiuhong Pang; Penghui Chen; Hao Wu; Tao Yang
Journal:  Neural Plast       Date:  2016-12-08       Impact factor: 3.599

8.  POU4F3 mutation screening in Japanese hearing loss patients: Massively parallel DNA sequencing-based analysis identified novel variants associated with autosomal dominant hearing loss.

Authors:  Tomohiro Kitano; Maiko Miyagawa; Shin-Ya Nishio; Hideaki Moteki; Kiyoshi Oda; Kenji Ohyama; Hiromitsu Miyazaki; Hiroshi Hidaka; Ken-Ichi Nakamura; Takaaki Murata; Rina Matsuoka; Yoko Ohta; Nobuhiro Nishiyama; Kozo Kumakawa; Sakiko Furutate; Satoshi Iwasaki; Takechiyo Yamada; Yumi Ohta; Natsumi Uehara; Yoshihiro Noguchi; Shin-Ichi Usami
Journal:  PLoS One       Date:  2017-05-17       Impact factor: 3.240

9.  Diverse spectrum of rare deafness genes underlies early-childhood hearing loss in Japanese patients: a cross-sectional, multi-center next-generation sequencing study.

Authors:  Hideki Mutai; Naohiro Suzuki; Atsushi Shimizu; Chiharu Torii; Kazunori Namba; Noriko Morimoto; Jun Kudoh; Kimitaka Kaga; Kenjiro Kosaki; Tatsuo Matsunaga
Journal:  Orphanet J Rare Dis       Date:  2013-10-28       Impact factor: 4.123

10.  Novel compound heterozygous mutations in MYO7A Associated with Usher syndrome 1 in a Chinese family.

Authors:  Xue Gao; Guo-Jian Wang; Yong-Yi Yuan; Feng Xin; Ming-Yu Han; Jing-Qiao Lu; Hui Zhao; Fei Yu; Jin-Cao Xu; Mei-Guang Zhang; Jiang Dong; Xi Lin; Pu Dai
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

View more
  5 in total

Review 1.  Gene therapy development in hearing research in China.

Authors:  Zhen Zhang; Jiping Wang; Chunyan Li; Wenyue Xue; Yazhi Xing; Feng Liu
Journal:  Gene Ther       Date:  2020-07-17       Impact factor: 5.250

2.  Four Novel Variants in POU4F3 Cause Autosomal Dominant Nonsyndromic Hearing Loss.

Authors:  Tian-Yi Cui; Xue Gao; Sha-Sha Huang; Yan-Yan Sun; Si-Qi Zhang; Xin-Xia Jiang; Yan-Zhong Yang; Dong-Yang Kang; Qing-Wen Zhu; Yong-Yi Yuan
Journal:  Neural Plast       Date:  2020-07-01       Impact factor: 3.599

3.  A Missense POU4F3 Variant Associated with Autosomal Dominant Midfrequency Hearing Loss Alters Subnuclear Localization and Transcriptional Capabilities.

Authors:  Dan Bai; Xudong Zhang; Yu Li; Jing Ni; Kai Lan
Journal:  Biomed Res Int       Date:  2021-06-21       Impact factor: 3.411

4.  Identification of two novel mutations in POU4F3 gene associated with autosomal dominant hearing loss in Chinese families.

Authors:  Xiaohui Bai; Fengguo Zhang; Yun Xiao; Yu Jin; Qingyin Zheng; Haibo Wang; Lei Xu
Journal:  J Cell Mol Med       Date:  2020-05-11       Impact factor: 5.310

5.  Comprehensive genetic testing of Chinese SNHL patients and variants interpretation using ACMG guidelines and ethnically matched normal controls.

Authors:  Yongyi Yuan; Qi Li; Yu Su; Qiongfen Lin; Xue Gao; Hankui Liu; Shasha Huang; Dongyang Kang; N Wendell Todd; Douglas Mattox; Jianguo Zhang; Xi Lin; Pu Dai
Journal:  Eur J Hum Genet       Date:  2019-09-20       Impact factor: 4.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.